More people are living longer. By 2050, 22% of the population in the United States will be over the age of 65. Unfortunately, living longer doesn’t necessarily equate with healthy aging. Older individuals often struggle with major diseases, such as Alzheimer’s disease, cancer and strokes. While academic researchers and biomedical companies have made great strides to improve the quality of life for the elderly, there remains a gap between academia and industry a disconnect that continues to slow the process of getting scientific discoveries from the researchers to the patients who need them.
Prepared to serve miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The "Alzheimer Disease - New Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com s offering..
/PRNewswire/ The "Alzheimer Disease - New Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com s offering..
Share this article
Share this article
ResearchAndMarkets.com s offering.
Profiles of 117 companies involved in developing diagnostics and therapeutics for Alzheimer s disease are presented along with 89 collaborations. The bibliography contains over 900 publications that are cited in the report.The report is supplemented with 48 tables and 27 figures.
Alzheimer s disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles. Several new approaches emphasize neuroprotection as well.